Dudediligence.

Gilead Sciences, Inc

GILDNASDAQ · Biological Products, (No Diagnostic Substances)
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$7.54BSep ’24$7.57BDec ’24$6.67BMar ’25$7.08BJun ’25$7.77BSep ’25$7.92BDec ’25$6.96BMar ’26$7.80BJun ’26
Net income, by quarter
$1.25BSep ’24$1.78BDec ’24$1.31BMar ’25$1.96BJun ’25$3.05BSep ’25$2.18BDec ’25$2.02BMar ’26−$10.50BJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue$27.30B$27.28B$27.12B$28.75B$29.44B
Gross profit$20.70B$21.62B$20.62B$22.50B$23.21B
Operating income$9.92B$7.33B$7.61B$1.66B$10.02B
Net income$6.22B$4.59B$5.67B$480.0M$8.51B
Operating cash flow$11.38B$9.07B$8.01B$10.83B$10.02B
Free cash flow$10.80B$8.34B$7.42B$10.30B$9.46B
Cash$5.34B$5.41B$6.08B$9.99B$7.56B
Debt$26.70B$25.23B$24.99B$26.71B$24.94B
Shares outstanding1.25B1.25B1.25B1.25B1.24B